EpiPen Buyers Tear Into Mylan, Pfizer Bid For Cert. Review
EpiPen buyers suing Mylan and Pfizer over the exorbitant cost of the emergency allergy treatment are fighting the drugmakers' push for a Tenth Circuit review of their class certification win, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article